Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
MEDP Stock Forecast 2026-2027
$424.00
Current Price
$12.11B
Market Cap
Buy 4
Hold 8
Sell 1
Wall St Analyst Ratings
Distance to MEDP Price Targets
+16.7%
To High Target of $495.00
+7.5%
To Median Target of $456.00
-22.4%
To Low Target of $329.00
MEDP Price Momentum
+1.5%
1 Week Change
-14.1%
1 Month Change
+43.2%
1 Year Change
-24.5%
Year-to-Date Change
-32.6%
From 52W High of $628.92
+49.0%
From 52W Low of $284.48
📊 TOP ANALYST CALLS
Did MEDP Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Medpace is one of their latest high-conviction picks.
Latest MEDP Stock Price Targets & Analyst Predictions
Based on our analysis of 19 Wall Street analysts, MEDP has a neutral consensus with a median price target of $456.00 (ranging from $329.00 to $495.00). The overall analyst rating is Buy (6.9/10). Currently trading at $424.00, the median forecast implies a 7.5% upside. This outlook is supported by 4 Buy, 8 Hold, and 1 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
MEDP Analyst Ratings
4
Buy
8
Hold
1
Sell
MEDP Price Target Range
Low
$329.00
Average
$456.00
High
$495.00
Current: $424.00
Latest MEDP Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for MEDP.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 24, 2026 | Barclays | Luke Sergott | Equal-Weight | Maintains | $450.00 |
| Apr 24, 2026 | Baird | Eric Coldwell | Outperform | Maintains | $477.00 |
| Apr 24, 2026 | BMO Capital | Sean Dodge | Market Perform | Maintains | $400.00 |
| Apr 24, 2026 | RBC Capital | Ryan Halsted | Outperform | Maintains | $484.00 |
| Mar 6, 2026 | Barclays | Luke Sergott | Equal-Weight | Upgrade | $500.00 |
| Mar 3, 2026 | RBC Capital | Ryan Halsted | Outperform | Initiates | $522.00 |
| Feb 18, 2026 | TD Cowen | Charles Rhyee | Hold | Upgrade | $419.00 |
| Feb 13, 2026 | Jefferies | David Windley | Buy | Upgrade | $560.00 |
| Feb 11, 2026 | Truist Securities | Jailendra Singh | Hold | Maintains | $539.00 |
| Feb 11, 2026 | Leerink Partners | Michael Cherny | Market Perform | Maintains | $485.00 |
| Feb 11, 2026 | Barclays | Luke Sergott | Underweight | Maintains | $500.00 |
| Dec 15, 2025 | Barclays | Luke Sergott | Underweight | Maintains | $525.00 |
| Nov 13, 2025 | BMO Capital | Sean Dodge | Market Perform | Initiates | $600.00 |
| Oct 27, 2025 | Truist Securities | Hold | Maintains | $N/A | |
| Oct 24, 2025 | TD Cowen | Charles Rhyee | Sell | Maintains | $462.00 |
| Oct 24, 2025 | Mizuho | Ann Hynes | Outperform | Maintains | $655.00 |
| Oct 24, 2025 | Barclays | Luke Sergott | Underweight | Maintains | $485.00 |
| Oct 17, 2025 | Mizuho | Ann Hynes | Outperform | Maintains | $575.00 |
| Oct 2, 2025 | Barclays | Luke Sergott | Underweight | Downgrade | $425.00 |
| Sep 9, 2025 | Jefferies | David Windley | Hold | Maintains | $450.00 |
Medpace Holdings Inc. (MEDP) Competitors
The following stocks are similar to Medpace based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Medpace Holdings Inc. (MEDP) Financial Data
Medpace Holdings Inc. has a market capitalization of $12.11B with a P/E ratio of 26.7x. The company generates $2.68B in trailing twelve-month revenue with a 17.2% profit margin.
Revenue growth is +26.5% quarter-over-quarter, while maintaining an operating margin of +20.0% and return on equity of +77.3%.
Valuation Metrics
Market Cap
$12.11B
Enterprise Value
$11.60B
P/E Ratio
26.7x
PEG Ratio
1.7x
Price/Sales
4.5x
Growth & Margins
Revenue Growth (YoY)
+26.5%
Gross Margin
+27.8%
Operating Margin
+20.0%
Net Margin
+17.2%
EPS Growth
+8.1%
Financial Health
Cash/Price Ratio
+5.4%
Current Ratio
0.8x
Debt/Equity
24.4x
ROE
+77.3%
ROA
+17.5%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Medpace Holdings Inc. (MEDP) Business Model
About Medpace Holdings Inc.
What They Do
Provides outsourced drug development and clinical trial services.
Business Model
Medpace operates as a full-service clinical contract research organization, generating revenue by offering a wide range of services related to drug development and clinical trials. The company caters to both small and midsize biopharmaceutical sponsors as well as larger pharmaceutical firms, helping them manage the complexities of clinical trials and regulatory requirements.
Additional Information
Founded in 1992 and headquartered in Cincinnati, Ohio, Medpace operates globally across multiple continents, leveraging scientific expertise and operational excellence to enhance drug development timelines and support the outsourcing needs of the clinical research environment.
Company Information
Sector
Healthcare
Industry
Diagnostics & Research
Employees
6,200
CEO
Dr. August James Troendle M.D.
Country
United States
IPO Year
2016
Website
www.medpace.comMedpace Holdings Inc. (MEDP) Latest News & Analysis
Latest News
Quick Summary
A class action lawsuit has been filed against Medpace Holdings, Inc. (NASDAQ: MEDP) for alleged securities violations under the Securities Exchange Act of 1934, as announced by Schall Law Firm.
Why It Matters
The class action lawsuit against Medpace could lead to financial penalties and impact the company's stock price, affecting investor returns and overall market perception.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Investors in Medpace Holdings Inc. (NASDAQ: MEDP) who bought shares between April 22, 2025, and February 9, 2026, can apply to be lead plaintiff in a class action lawsuit by June 8, 2026.
Why It Matters
The announcement signals potential legal risks for Medpace Holdings, which could impact the stock price and investor sentiment regarding company stability and governance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Faruqi & Faruqi is investigating claims against Medpace (NASDAQ: MEDP) for investors who suffered losses between April 22, 2025, and February 9, 2026. A lead plaintiff deadline is set for June 8, 2026.
Why It Matters
The investigation and potential class action against Medpace may indicate financial instability or legal issues, affecting investor confidence and stock performance.
Source: Newsfile Corp
Market Sentiment:
Neutral
Quick Summary
A class action lawsuit has been filed against Medpace Holdings Inc. for securities fraud, following significant stock drops. Investors are advised to seek more information on the case.
Why It Matters
The class action lawsuit against Medpace Holdings for securities fraud could lead to financial penalties and further stock declines, impacting investor confidence and market value.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Medpace Holdings, Inc. (NASDAQ: MEDP) shareholders are encouraged to contact the Gross Law Firm about potential lead plaintiff appointments for a class action lawsuit.
Why It Matters
Shareholder lawsuits can impact stock price and investor sentiment, highlighting potential risks related to Medpace Holdings' governance or performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
A class action lawsuit has been filed against Medpace Holdings, Inc. for alleged federal securities law violations affecting investors from April 22, 2025, to February 9, 2026.
Why It Matters
The class action lawsuit against Medpace Holdings could lead to financial liabilities and reputational damage, affecting stock performance and investor confidence in the company.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About MEDP Stock
What is Medpace Holdings Inc.'s (MEDP) stock forecast for 2026?
Based on our analysis of 19 Wall Street analysts, Medpace Holdings Inc. (MEDP) has a median price target of $456.00. The highest price target is $495.00 and the lowest is $329.00.
Is MEDP stock a good investment in 2026?
According to current analyst ratings, MEDP has 4 Buy ratings, 8 Hold ratings, and 1 Sell ratings. The stock is currently trading at $424.00. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for MEDP stock?
Wall Street analysts predict MEDP stock could reach $456.00 in the next 12 months. This represents a 7.5% increase from the current price of $424.00. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Medpace Holdings Inc.'s business model?
Medpace operates as a full-service clinical contract research organization, generating revenue by offering a wide range of services related to drug development and clinical trials. The company caters to both small and midsize biopharmaceutical sponsors as well as larger pharmaceutical firms, helping them manage the complexities of clinical trials and regulatory requirements.
What is the highest forecasted price for MEDP Medpace Holdings Inc.?
The highest price target for MEDP is $495.00 from at , which represents a 16.7% increase from the current price of $424.00.
What is the lowest forecasted price for MEDP Medpace Holdings Inc.?
The lowest price target for MEDP is $329.00 from at , which represents a -22.4% decrease from the current price of $424.00.
What is the overall MEDP consensus from analysts for Medpace Holdings Inc.?
The overall analyst consensus for MEDP is neutral. Out of 19 Wall Street analysts, 4 rate it as Buy, 8 as Hold, and 1 as Sell, with a median price target of $456.00.
How accurate are MEDP stock price projections?
Stock price projections, including those for Medpace Holdings Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 10, 2026 1:08 PM UTC